Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (NCT04919226)
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Center — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- Stanford Cancer Center — Palo Alto, California
- University of Colorado Hospital, Nuclear Medicine — Aurora, Colorado
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic - Rochester, Department of Oncology — Rochester, Minnesota
- Washington University Alvin J. Siteman Cancer Center — St Louis, Missouri
- Memorial Sloan-Kettering Cancer Center — New York, New York
- ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute — New York, New York
- Duke University School of Medicine, Duke Cancer Institute — Durham, North Carolina
- Oregon Health and Science University — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Texas Oncology — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
- Royal North Shore Hospital — St Leonards, New South Wales
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Fudan University Shanghai Cancer Center — Shanghai,
- Affiliated Hospital of Jiangnan University — Wuxi,
- Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology — Pessac, Bordeaux
- Nantes University Hospital Center - Hotel Dieu Hospital — Nantes, Cedex
- Edouard Herriot Hospital, Medical Oncology Unit — Lyon,
- IUCT Oncopole - Institut Universitaire du Cancer de Toulouse — Toulouse,
- Charite - University Hospital Berlin — Berlin,
- University Hospital Bonn, Department of Nuclear Medicine — Bonn,
- University Hospital Erlangen, Department of Internal Medicine I - Endocrinology — Erlangen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroendocrine Tumors
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients — Denver, Colorado
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors — Hamilton, Ontario
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors — Iowa City, Iowa
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Gilbert, Arizona
- Post-Authorization Long-Term Safety Study of LUTATHERA — Phoenix, Arizona
- Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors — Edmonton, Alberta
Explore by condition: All Neuroendocrine Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.